Chih-Yi Liao, MD, discusses outcomes reported with ivosidenib in patients with advanced cholangiocarcinoma.
Chih-Yi Liao, MD, assistant professor of medicine, University of Chicago Department of Medicine, discusses outcomes reported with ivosidenib (Tibsovo) in patients with advanced cholangiocarcinoma.
In the phase 3 ClarIDHy trial (NCT02989857), the agent was examined vs placebo in patients with IDH1-mutant, advanced cholangiocarcinoma. The primary end point of the trial was progression-free survival (PFS), which was met, according to Liao. Ivosidenib resulted in a PFS of 2.7 months vs 1.4 months with placebo in this population, Liao says. Although this may not seem numerically significant, it translates a 63% reduction in the risk of progression or death, Liao notes.
In terms of overall survival (OS), the median OS in patients who received treatment with ivosidenib was 10.3 months vs 7.5 months in those who were given placebo, Liao adds. Despite the numeric improvement, this was not found to be statistically significant, Liao concludes.